Anterior Uveitis Treatment Market Size, Share & Trends Analysis Report By Type (Infectious Uveitis), By Therapy (Biologics), By Distribution Channel (Hospital, Retail, Online Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED: August 2, 2024

PAGES: 120 Pages

DELIVERY TIME: 2-10 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Anterior Uveitis Treatment Market Growth & Trends:

The global anterior uveitis treatment market size is expected to reach USD 967.5 million by 2030, registering a CAGR of 12.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of the disease is anticipated to aid market growth. This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.

According to a 2017 article by Retina Today, this condition accounted for around 30% to 90% of the cases of uveitis. It also stated around 1% to 4% of patients experience 25% loss of visual acuity. There are different effective treatments for this disease and can be easily managed; however, it tends to recur. This disease is prevalent among both young and middle-aged group. It is also common among the geriatric population. Ocular ischemia and herpetic uveitis are the two most common causes of this disease among the geriatric population. Most of the cases occur in healthy people, however, some are associated with infectious diseases, gastrointestinal disorders, rheumatologic diseases, and lung & skin diseases. This disease is less sight-threatening as compared to posterior uveitis, however, in some cases might lead to glaucoma, cataract, and cystoid macular edema.

Anterior Uveitis Treatment Market Report Highlights:

Corticosteroids dominated the anterior uveitis treatment market in 2023 owing to its beneficial characteristic of minimizing inflammation in the eye. It is the primary treatment modality.
Anti-TNF agents are expected to exhibit lucrative growth rate over the forecast period due to growing opportunity in treatment methods with biologic therapy using Anti-TNF drugs.
Immunosuppressants held a significant market share in 2023 owing to their growing adoption for treatment of chronic anterior uveitis.
Hospital pharmacies dominated the market in 2023 due to the wide treatment options available there.
Online pharmacies are expected to witness significant CAGR over the forecast period due to convenience, ease, and availability of discounted products.
North America held the largest revenue share in 2023 owing to high prevalence as well as healthcare expenditure in this region.
Asia Pacific is anticipated to exhibit lucrative growth during the forecast period due to the rising number of infectious diseases in developing countries of the region and growing disposable income.

Product Code: GVR-3-68038-450-5

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Anterior Uveitis Treatment Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Anterior Uveitis Treatment Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Anterior Uveitis Treatment Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Anterior Uveitis Treatment Market: Type Movement Analysis, 2023 & 2030 (USD Million)
4.3. Infectious Uveitis
- 4.3.1. Infectious Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Non-Infectious Uveitis
- 4.4.1. Non-Infectious Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.4.1.1. Anterior Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.4.1.2. Pan-Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.4.1.3. Posterior Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.4.1.4. Intermediate Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Anterior Uveitis Treatment Market: Therapy Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Anterior Uveitis Treatment Market: Therapy Movement Analysis, 2023 & 2030 (USD Million)
5.3. Corticosteroids
- 5.3.1. Corticosteroids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Immunosuppressive Therapies
- 5.4.1. Immunosuppressive Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Biologics
- 5.5.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Others
- 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Pipeline Therapies
- 5.7.1. Pipeline Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Anterior Uveitis Treatment Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Anterior Uveitis Treatment Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacies
- 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
- 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacies
- 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Anterior Uveitis Treatment Market: Regional Estimates & Trend Analysis

7.1. Anterior Uveitis Treatment Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
- 7.2.1. North America Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. U K Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Japan Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. China
  - 7.4.3.1. China Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. Australia
  - 7.4.5.1. Australia Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. UAE
  - 7.6.4.1. UAE Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Novartis AG
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Santen Pharmaceutical Co., Ltd
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. AbbVie Inc.
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Kiora Pharmaceuticals, Inc.
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Clearside Biomedical
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Aldeyra Therapeutics, Inc.
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. UCB S.A.
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Agilent Technologies, Inc. (Lux Biosciences, Inc.)
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Tarsier Pharma Ltd.
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives